BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide today announced that its BTK inhibitor BRUKINSA™ (zanubrutinib) has been approved by the Ministry of Health in Kuwait, the National Health Regulatory Authority in Bahrain and the Ministry of Public Health in Qatar for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
- Read more about BeiGene announces BRUKINSA (zanubrutinib) Is approved in 50 Markets
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/beigene-announces-brukinsa-zanubrutinib-is-approved-in-50-markets
No comments:
Post a Comment